44-LB: Insulin Treatment Satisfaction Questionnaire Results for PRONTO-Pump-2 Study
| Autor: | Debra A. Ignaut, Carolina Piras De Oliveira, Rosirene Paczkowski, Rattan Juneja, Jiat Ling Poon, Jang Ik Cho, Emily R. Hankosky |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Diabetes. 70 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | Background: In PRONTO-Pump-2, a Phase 3, 16-week, randomized, double-blind clinical trial in patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII), ultra rapid lispro (URLi; a novel mealtime insulin), showed superior postprandial glucose control and noninferior HbA1c reduction, with less hypoglycemia compared to Humalog® (Lispro). We assessed treatment satisfaction in patients enrolled in this trial (URLi, N=215; Humalog, N=217), using the Insulin Treatment Satisfaction Questionnaire (ITSQ). Methods: The ITSQ was administered to patients at baseline and endpoint (week 16 or early discontinuation). The 5 domains assessed were glycemic control, hypoglycemic control, insulin delivery device, inconvenience of regimen, and lifestyle flexibility. Domain scores were transformed to a scale of 0-100 for analysis, with higher scores indicating better treatment satisfaction. The change in each domain-specific and overall transformed score from baseline to endpoint (last observation carried forward) was analyzed using an ANCOVA model. Results: At endpoint, for patients treated with URLi, glycemic control scores had increased from a baseline of 66.9 by +7.0 (standard error [SE] 1.59; p Conclusion: Patients with type 1 diabetes treated with URLi using CSII reported to be satisfied with the glycemic control they experienced and perceived URLi treatment to be more convenient than Humalog. Disclosure C. Piras de oliveira: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. R. Paczkowski: Employee; Self; Eli Lilly and Company, Employee; Spouse/Partner; Amgen Inc., Stock/Shareholder; Self; Eli Lilly and Company, Stock/Shareholder; Spouse/Partner; Amgen Inc. J. Cho: None. R. Juneja: Employee; Self; Eli Lilly and Company. J. Poon: Employee; Self; Eli Lilly and Company. E. R. Hankosky: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. D. A. Ignaut: Employee; Self; Eli Lilly and Company. Funding Eli Lilly and Company |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|